Videos

The session emphasized how rapidly evolving AI technologies are addressing long-standing inefficiencies in urologic care.

Walter R. Hsiang, MD, MBA, highlights a study looking at access to care, insurance acceptance, wait times, and costs for stone disease management.

Aleece Fosnight, MSPAS, PA-C, highlights pattern recognition as a cornerstone of diagnosis, encouraging clinicians to closely examine how urinary symptoms fluctuate across the menstrual cycle.

A key finding was that among the qualities applicants highlighted, only “learning and growth” correlated with interview selection.

Maxwell L. Sandberg, MD, highlights a study on survival outcomes between patients who underwent CN-TT via an open, laparoscopic, or robotic approach.

Notable findings highlighted stark differences between this safety-net population and national averages.

Fed Ghali, MD, discusses the phase 2 CONSOLIdaTE-01 trial, assessing the role for consolidative local therapy following disease control on EV/P.

Jennifer Miles-Thomas, MD, URPS, MBA, emphasizes that teleurology and team-based care models offer significant promise

Mark D. Tyson, II, MD, MPH, highlights interim findings from the ADVANCED-2 trial of TARA-002 in BCG-naïve NMIBC.

Discover essential tips for new users on rectal spacers, including collaboration, training, and enhancing patient care in radiation oncology.

Experts discuss evolving treatment strategies for metastatic castration-resistant prostate cancer, emphasizing personalized therapy and innovative options.

Experts discuss evolving treatment strategies for metastatic castration-resistant prostate cancer, emphasizing personalized therapy and innovative options.

Patients learn about the benefits of rectal spacers in radiation therapy, easing concerns and enhancing treatment comfort and safety.

The study retrospectively analyzed 456 biopsy-naive men who underwent PHI testing followed by a prostate biopsy.

In the final installment in a 5-part series, Richard Wassersug, PhD, and Paul F. Schellhammer, MD, FACS, discuss strategies for establishing transdermal estradiol as a recognized therapy for men undergoing androgen deprivation therapy for prostate cancer.

In part 4 of a 5-part series, Richard Wassersug, PhD, and Paul F. Schellhammer, MD, FACS, focus on concerns about the adverse events of transdermal estradiol, particularly gynecomastia.

In part 3 of a 5-part series, Richard Wassersug, PhD, and Paul F. Schellhammer, MD, FACS, discuss emerging evidence supporting transdermal estradiol as an effective and potentially superior alternative to traditional LHRH analogue ADT for advanced prostate cancer.

In part 2 of a 5-part series, Richard Wassersug, PhD, and Paul F. Schellhammer, MD, FACS, explore the historical, clinical, and systemic barriers to using transdermal estradiol as a treatment for prostate cancer, while highlighting its potential benefits.

In this opening segment, Richard Wassersug, PhD, and Paul F. Schellhammer, MD, FACS, discuss the origins, goals, and challenges of the Estradiol Initiative.

The expert faculty discuss how to approach management for patients who experience NMIBC recurrence after receiving combination BCG and checkpoint inhibitor therapy.

The expert faculty explore complex clinical scenarios involving patients who progress to muscle-invasive bladder cancer (MIBC) after receiving prior immunotherapy for high-risk NMIBC.

Harras Zaid, MD, discusses the complex decision-making involved in managing renal tumors with associated tumor thrombus.

Tom Jayram, MD, discusses the phase 2 SURF302 trial of TYRA-300, a FGFR3-selective inhibitor for FGFR3-altered LG-IR-NMIBC.

Explore the evolving landscape of immunotherapy in prostate cancer, focusing on personalized treatments and innovative combination strategies.

Explore the evolving landscape of prostate cancer treatment, focusing on personalized immunotherapy and effective patient management strategies.

Fed Ghali, MD, highlights simulated outcomes of the EV-302 trial when adjusting for use of maintenance avelumab in the control arm.

One of the most notable changes is a new thematic structure within urologic oncology.

The study assessed descriptive sequencing and oncologic outcomes among patients receiving gene therapy for BCG-unresponsive NMIBC.

Jim C. Hu, MD, MPH, discusses the functional advantages of a posterior approach to endopelvic neurovascular total sparing (PATENTS) robotic-assisted radical prostatectomy.

Healthcare professionals discuss patient selection, treatment strategies, and compliance tools for managing advanced prostate cancer effectively.